# CIRCADIAN REGULATION OF HIF2alpha IN RENAL CELL CARCINOMA

> **NIH NIH R01** · SCRIPPS RESEARCH INSTITUTE, THE · 2022 · $100,451

## Abstract

PROJECT SUMMARY (DESCRIPTION)
Clear cell renal cell carcinoma (ccRCC) is frequently driven by increased activity of the hypoxia-inducible
transcription factor HIF2a. Circadian rhythms coordinate behavior and physiology with predictable daily
environmental cycles. Chronic disruption of circadian rhythms, such as that experienced during shift work or
travel across time zones, increases the risk of several types of cancer in people. We have established that the
circadian clock components BMAL1, CRY1, and CRY2 regulate the activity of HIF2a, indicating that
pharmacological targeting of the circadian clock presents a new therapeutic opportunity for suppressing HIF2a
in ccRCC.
To provide additional preliminary data to support the feasibility of the proposed next phase of this project in
response to reviewers’ concerns, we need additional time to establish renal cell carcinoma xenograft models in
male and female immunocompromised host mice in the Lamia Lab.

## Key facts

- **NIH application ID:** 10613272
- **Project number:** 3R01CA211187-05S1
- **Recipient organization:** SCRIPPS RESEARCH INSTITUTE, THE
- **Principal Investigator:** Katja A Lamia
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $100,451
- **Award type:** 3
- **Project period:** 2022-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10613272

## Citation

> US National Institutes of Health, RePORTER application 10613272, CIRCADIAN REGULATION OF HIF2alpha IN RENAL CELL CARCINOMA (3R01CA211187-05S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10613272. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*